3/28/2005

Teva Pharmaceutical received tentative FDA approval for marketing its generic version of Pfizer's Norvasc for treating hypertension and angina, worth $2.4 billion in annual sales for Pfizer. Teva said it expects final agency approval once Pfizer's patent on the drug expires in September 2007.

Full Story:
NYTimes.com

Related Summaries